Bone metabolism and peritoneal membrane transport in children on chronic peritoneal dialysis

Peritoneal Dialysis International

Volumn 23, Issue 5, 2003, Pages 487-492

  Ziólkowska, Helena ^a,c   Pańczyk Tomaszewska, Malgorzata ^a   Dȩbiński, Andrzej ^b   Sawicki, Andrzej ^b   Roszkowska Blaim, Maria ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL FOOD AND NUTRITION INSTITUTE   (Poland)

^c University Hospital   (Poland)

Author keywords

Bone metabolism; Children; End stage renal failure; Peritoneal transport

Indexed keywords

ALBUMIN; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; CREATININE; GLUCOSE; PARATHYROID HORMONE; PHOSPHORUS; PROTEIN;

ADOLESCENT; AGE; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; BONE BIOPSY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; FEMALE; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MALE; MEDICAL ASSESSMENT; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; OSSIFICATION; OSTEOCLAST; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; STANDARD; STATISTICAL SIGNIFICANCE; TIME;

EID: 0142150140     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080302300515     Document Type: Article

References (19)

1. Davies SJ, Phillips L, Russell GI. Peritoneal solute transport predicts survival on CAPD independently of residual renal function. Nephrol Dial Transplant 1998; 13:962-8.
2. Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B. Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 1998; 13:1242-9.
3. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
4. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, et al. Bone histomorphometry: standardization of nomenclature, symbols and units. J Bone Miner Res 1987; 2:596-610.
5. Sawicki A, Debinski A, Polowiec Z. Histomorphometric evaluation of non-decalcified bone tissue in healthy children and young adults. Med Sci Monit 1998; 4(Suppl 2):130-2.
6. Fournier A, Moriniere P, Marie A. Adynamic bone disease - is it actually a disease? Nephrol Dial Transplant 1995; 10:454-7.
7. Cohen-Solal ME, Sebert JL, Boudailliez B, Westeel PF, Moriniere PH, Marie A, et al. Non-aluminic adynamic bone disease in non-dialyzed uremic patients: a new type of osteopathy due to overtreatment? Bone 1992; 13:1-5.
8. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 1989; 125: 1805-13.
9. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988; 123:2600-2.
10. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, et al. Interleukin-6. A potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992; 89:46-52.
11. Zemel D, ten Berge RJM, Struijk DG, Bloemena E, Koomen GCM, Krediet RT. Interleukin 6 in CAPD patients without peritonitis: relationship to the intrinsic permeability of the peritoneal membrane. Clin Nephrol 1992; 37:97-103.
12. Wang T, Heimbürger O, Cheng HH, Bergström J, Lindholm B. Does a high peritoneal transport rate reflect a state of chronic inflammation? Perit Dial Int 1999; 19:17-22.
13. Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res 1999; 14:2150-8.
14. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001; 142:4349-56.
15. Bereket G, Lin JJ, Bereket A, Lang CH, Kaskel FJ. Peritoneal loss of insulin-like growth factor-I and binding proteins in end-stage renal disease. Pediatr Nephrol 1998; 12:581-8.
16. Wang T, Chen YG, Ye RG, Li SL, Li HQ, Chen YX. Effect of glucose on TGF-beta 1 expression in peritoneal mesothelial cells. Adv Perit Dial 1995; 11:7-10.
17. Murakami T, Yamamoto M, Ono K, Nishikawa M, Nagata N, Motoyoshi K, et al. Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 1998; 252:747-52.
18. Bursch W, Oberhammer F, Jirtle RL, Askari M, Sedivy R, Grasl-Kraupp B, et al. Transforming growth factor betal as a signal for induction of cell death by apoptosis. Br J Cancer 1992; 67:531-6.
19. Fujimoto R, Tanizawa T, Nishida S, Yamamoto N, Soshi S, Endo N, et al. Local effects of transforming growth factor beta-1 on rat calvaria: changes depending on the dose and the injection site. J Bone Miner Metab 1999; 17:11-17.